Here's What AstraZeneca's Recent FDA News Means for Shareholders
Copyright 1995-2022 The Motley Fool. All rights reserved.
finance
2022-05-28 12:15:00

On April 25, AstraZeneca's (AZN 1.05%) biologics license application for its tremelimumab and Imfinzi drug pairing was accepted by the U.S. Food and Drug Administration (FDA) to treat patients with advanced, unresectable liver cancer.Â 
With the FDA expected to make a decision by the fourth quarter of 2022, it's worth asking the following question: How much in sales could the drug combo generate for the pharma stock if approved? Let's take a glance at the clinical trial results for the drug pairing and the U.
